drugset / Trial / NCT00247988
Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Weekly carboplatin and taxotere will be tolerable and effective as second line treatment of platinum-sensitive ( \>6 month treatment free interval) relapsed ovarian cancer Primary efficacy parameter will be response rate (CR and PR) according to RECIST criteria. Secondary endpoints will be duration of response, progression free survival and overall survival. Toxicity will also be evaluated.
Timeline
- Start
- 2003-10
- Primary completion
- —
- Completion
- 2007-04
Outcome
Outcome not reported
Stopped: “Regulatory issues(trial temporarily suspended December 28, 2005. Permanently suspended January 19, 2007. Institutional Reveiw Board informed April 18, 2007”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | 35 mg/m2 | — |
Indications
No indication recorded.